Telix Pharmaceuticals Limited

ASX:TLX Stock Report

Market Cap: AU$8.3b

Telix Pharmaceuticals Management

Management criteria checks 4/4

Telix Pharmaceuticals' CEO is Chris Behrenbruch, appointed in Jul 2023, has a tenure of 1.42 years. total yearly compensation is A$1.02M, comprised of 49% salary and 51% bonuses, including company stock and options. directly owns 6.94% of the company’s shares, worth A$574.67M. The average tenure of the management team and the board of directors is 2.3 years and 7.3 years respectively.

Key information

Chris Behrenbruch

Chief executive officer

AU$1.0m

Total compensation

CEO salary percentage49.0%
CEO tenure1.4yrs
CEO ownership6.9%
Management average tenure2.3yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Behrenbruch's remuneration changed compared to Telix Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

AU$49m

Mar 31 2024n/an/a

AU$32m

Dec 31 2023AU$1mAU$499k

AU$5m

Sep 30 2023n/an/a

-AU$21m

Jun 30 2023n/an/a

-AU$48m

Mar 31 2023n/an/a

-AU$77m

Dec 31 2022AU$865kAU$422k

-AU$104m

Sep 30 2022n/an/a

-AU$111m

Jun 30 2022n/an/a

-AU$119m

Mar 31 2022n/an/a

-AU$100m

Dec 31 2021AU$620kAU$374k

-AU$81m

Sep 30 2021n/an/a

-AU$70m

Jun 30 2021n/an/a

-AU$59m

Mar 31 2021n/an/a

-AU$52m

Dec 31 2020AU$421kAU$295k

-AU$45m

Sep 30 2020n/an/a

-AU$40m

Jun 30 2020n/an/a

-AU$36m

Mar 31 2020n/an/a

-AU$32m

Dec 31 2019AU$460kAU$317k

-AU$28m

Sep 30 2019n/an/a

-AU$23m

Jun 30 2019n/an/a

-AU$19m

Mar 31 2019n/an/a

-AU$16m

Dec 31 2018AU$380kAU$280k

-AU$14m

Sep 30 2018n/an/a

-AU$12m

Jun 30 2018n/an/a

-AU$10m

Mar 31 2018n/an/a

-AU$8m

Dec 31 2017AU$303kAU$211k

-AU$6m

Compensation vs Market: Chris's total compensation ($USD636.98K) is below average for companies of similar size in the Australian market ($USD2.72M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Behrenbruch (48 yo)

1.4yrs

Tenure

AU$1,018,461

Compensation

Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharm...

Leadership Team

NamePositionTenureCompensationOwnership
Christian Behrenbruch
Co-Founder1.4yrsAU$1.02m6.94%
A$ 574.7m
Darren Smith
Group Chief Financial Officer2.3yrsAU$713.90k0.0019%
A$ 160.6k
Andreas Kluge
Chief Medical Advisorno dataAU$43.00k6.78%
A$ 561.0m
David Cade
Group Chief Medical Officerless than a yearno data0.11%
A$ 9.2m
Richard Valeix
Chief Executive Officer of Telix Therapeutics3.6yrsAU$902.90k0.060%
A$ 4.9m
Darren Patti
Group Chief Operating Officerless than a yearno data0%
A$ 0
Michael Wheatcroft
Chief Scientist3.6yrsAU$167.76kno data
Craig Ulrick
Chief Information Officer1.9yrsno datano data
Kyahn Williamson
Senior Vice President of Corporate Communications & Investor Relations3.4yrsno datano data
Lena Moran-Adams
Group General Counsel2.3yrsno datano data
Thomas Fromm
Vice President of Salesno datano datano data
Meredith Crowe
Senior Vice President of Global People & Culture2.3yrsno datano data

2.3yrs

Average Tenure

53.5yo

Average Age

Experienced Management: TLX's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christian Behrenbruch
Co-Founder7.9yrsAU$1.02m6.94%
A$ 574.7m
Harry McCann
Independent Non-Executive Chairman7.3yrsAU$188.28k0.34%
A$ 28.5m
Chaitanya Divgi
Member of the Scientific Advisory Boardno datano datano data
Rodney Hicks
Member of the Scientific Advisory Boardno datano datano data
Neil Bander
Member of the Scientific Advisory Boardno datano datano data
Mark Nelson
Independent Non-Executive Director7.3yrsAU$103.30k1.08%
A$ 89.8m
Jann Skinner
Independent Non-Executive Director6.5yrsAU$111.56k0.18%
A$ 14.7m
Jean-François Chatal
Member of the Scientific Advisory Boardno datano datano data
Jason Lewis
Member of the Scientific Advisory Boardno datano datano data
Klaus Kopka
Member of the Scientific Advisory Boardno datano datano data
Samuel Samnick
Member of the Scientific Advisory Boardno datano datano data
Richard Baum
Member of the Scientific Advisory Boardno datano datano data

7.3yrs

Average Tenure

65yo

Average Age

Experienced Board: TLX's board of directors are considered experienced (7.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 03:53
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Telix Pharmaceuticals Limited is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightBarclay Pearce Capital Pty Limited
John HesterBell Potter
Andrew PaineCLSA